Etaracizumab Explained

Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer[1] and various other types of cancer.[2] It is manufactured by MedImmune.[3]

It is an enhanced iteration of Vitaxin, also known as MEDI-523. Both are derived from the mouse antibody LM609.[4]

Notes and References

  1. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK . 6 . Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer . Neoplasia . 10 . 11 . 1259–67 . November 2008 . 18953435 . 2570602 . 10.1593/neo.08740 .
  2. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S . 6 . Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors . Investigational New Drugs . 26 . 1 . 35–43 . February 2008 . 17876527 . 10.1007/s10637-007-9077-0 . 37221398 .
  3. Web site: Etaracizumab . Statement On A Nonproprietary Name Adopted By The Usan Council .
  4. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G . 6 . Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion . Clinical Cancer Research . 11 . 21 . 7851–60 . November 2005 . 16278408 . 10.1158/1078-0432.CCR-05-0262 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etaracizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.